MX350875B - Formas de dosificacion farmaceutica de liberacion controlada. - Google Patents
Formas de dosificacion farmaceutica de liberacion controlada.Info
- Publication number
- MX350875B MX350875B MX2013010987A MX2013010987A MX350875B MX 350875 B MX350875 B MX 350875B MX 2013010987 A MX2013010987 A MX 2013010987A MX 2013010987 A MX2013010987 A MX 2013010987A MX 350875 B MX350875 B MX 350875B
- Authority
- MX
- Mexico
- Prior art keywords
- dosage forms
- controlled release
- pharmaceutical dosage
- release pharmaceutical
- layer
- Prior art date
Links
- 239000002552 dosage form Substances 0.000 title abstract 3
- 238000013270 controlled release Methods 0.000 title 1
- 239000013543 active substance Substances 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 238000004519 manufacturing process Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2893—Tablet coating processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161467824P | 2011-03-25 | 2011-03-25 | |
| PCT/IB2012/000595 WO2012131463A2 (en) | 2011-03-25 | 2012-03-22 | Controlled release pharmaceutical dosage forms |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2013010987A MX2013010987A (es) | 2014-10-13 |
| MX350875B true MX350875B (es) | 2017-09-19 |
Family
ID=46018006
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2013010987A MX350875B (es) | 2011-03-25 | 2012-03-22 | Formas de dosificacion farmaceutica de liberacion controlada. |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US20140056979A1 (enExample) |
| EP (1) | EP2688556B1 (enExample) |
| JP (1) | JP5964940B2 (enExample) |
| KR (1) | KR101619579B1 (enExample) |
| CN (1) | CN103547259A (enExample) |
| AU (1) | AU2012235878B2 (enExample) |
| BR (1) | BR112013024585A8 (enExample) |
| CA (1) | CA2831218C (enExample) |
| CY (1) | CY1116579T1 (enExample) |
| DK (1) | DK2688556T3 (enExample) |
| ES (1) | ES2544735T3 (enExample) |
| HR (1) | HRP20150835T1 (enExample) |
| HU (1) | HUE026981T2 (enExample) |
| IL (1) | IL228441B (enExample) |
| ME (1) | ME02189B (enExample) |
| MX (1) | MX350875B (enExample) |
| PH (1) | PH12013501994A1 (enExample) |
| PL (1) | PL2688556T3 (enExample) |
| PT (1) | PT2688556E (enExample) |
| RS (1) | RS54152B1 (enExample) |
| SI (1) | SI2688556T1 (enExample) |
| SM (1) | SMT201500209B (enExample) |
| WO (1) | WO2012131463A2 (enExample) |
| ZA (1) | ZA201307862B (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1407884B (zh) | 1999-10-29 | 2012-06-20 | 欧罗赛铁克股份有限公司 | 控释氢可酮制剂 |
| US10179130B2 (en) | 1999-10-29 | 2019-01-15 | Purdue Pharma L.P. | Controlled release hydrocodone formulations |
| WO2002036099A1 (en) | 2000-10-30 | 2002-05-10 | Euro-Celtique S.A. | Controlled release hydrocodone formulations |
| EP2957281A1 (en) | 2001-09-21 | 2015-12-23 | Egalet Ltd. | Polymer release system |
| US20040253310A1 (en) | 2001-09-21 | 2004-12-16 | Gina Fischer | Morphine polymer release system |
| ES2360102T3 (es) | 2003-03-26 | 2011-05-31 | Egalet A/S | Sistema para la liberación controlada de morfina. |
| EP2155167A2 (en) | 2007-06-04 | 2010-02-24 | Egalet A/S | Controlled release pharmaceutical compositions for prolonged effect |
| AU2010211220B2 (en) | 2009-02-06 | 2013-08-01 | Egalet Ltd. | Immediate release composition resistant to abuse by intake of alcohol |
| NZ603579A (en) | 2009-06-24 | 2014-02-28 | Egalet Ltd | Controlled release formulations |
| AP3815A (en) | 2010-12-22 | 2016-09-30 | Purdue Pharma Lp | Encased tamper resistant controlled release dosage forms |
| PH12013501345A1 (en) | 2010-12-23 | 2022-10-24 | Purdue Pharma Lp | Tamper resistant solid oral dosage forms |
| EP2844236B1 (en) | 2012-04-17 | 2018-12-19 | Purdue Pharma LP | Systems and methods for treating an opioid-induced adverse pharmacodynamic response |
| NZ704011A (en) | 2012-07-06 | 2016-04-29 | Egalet Ltd | Abuse deterrent pharmaceutical compositions for controlled release |
| SG11201506064UA (en) | 2013-02-05 | 2015-08-28 | Purdue Pharma Lp | Tamper resistant pharmaceutical formulations |
| US10751287B2 (en) | 2013-03-15 | 2020-08-25 | Purdue Pharma L.P. | Tamper resistant pharmaceutical formulations |
| JP6539274B2 (ja) | 2013-08-12 | 2019-07-03 | ファーマシューティカル マニュファクチュアリング リサーチ サービシズ，インコーポレーテッド | 押出成形された即放性乱用抑止性丸剤 |
| US9492444B2 (en) | 2013-12-17 | 2016-11-15 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
| WO2015095391A1 (en) | 2013-12-17 | 2015-06-25 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
| EP3169315B1 (en) | 2014-07-17 | 2020-06-24 | Pharmaceutical Manufacturing Research Services, Inc. | Immediate release abuse deterrent liquid fill dosage form |
| US9132096B1 (en) | 2014-09-12 | 2015-09-15 | Alkermes Pharma Ireland Limited | Abuse resistant pharmaceutical compositions |
| US9849124B2 (en) | 2014-10-17 | 2017-12-26 | Purdue Pharma L.P. | Systems and methods for treating an opioid-induced adverse pharmacodynamic response |
| US20160106737A1 (en) | 2014-10-20 | 2016-04-21 | Pharmaceutical Manufacturing Research Services, Inc. | Extended Release Abuse Deterrent Liquid Fill Dosage Form |
| US9839212B2 (en) | 2015-04-16 | 2017-12-12 | Bio-Lab, Inc. | Multicomponent and multilayer compacted tablets |
| KR20200022026A (ko) | 2017-06-30 | 2020-03-02 | 퍼듀 퍼머 엘피 | 치료 방법 및 이의 약형 |
| JP7335870B2 (ja) * | 2017-08-31 | 2023-08-30 | パーデュー、ファーマ、リミテッド、パートナーシップ | 医薬剤形 |
| IL273627B2 (en) | 2017-12-20 | 2025-03-01 | Purdue Pharma Lp | Morphine sulfate dosage forms for abuse deterrence |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR950007907B1 (ko) * | 1992-09-01 | 1995-07-21 | 동국제약 주식회사 | 치주질환 치료용 막형 국소약물송달제제 |
| US5567439A (en) * | 1994-06-14 | 1996-10-22 | Fuisz Technologies Ltd. | Delivery of controlled-release systems(s) |
| US5634702A (en) | 1995-09-27 | 1997-06-03 | Fistonich; Juraj | Hands free waste container having a closed cover that automatically opens when the container is moved outside its cabinet enclosure |
| PT1251832E (pt) * | 2000-02-04 | 2007-01-31 | Depomed Inc | Forma de dosagem constituída por invólucro-e-núcleo que conduz a uma libertação do fármaco de ordem zero |
| WO2002036099A1 (en) * | 2000-10-30 | 2002-05-10 | Euro-Celtique S.A. | Controlled release hydrocodone formulations |
| AU2005259476B2 (en) * | 2004-07-01 | 2010-07-29 | Gruenenthal Gmbh | Oral dosage form safeguarded against abuse |
| US7434308B2 (en) * | 2004-09-02 | 2008-10-14 | International Business Machines Corporation | Cooling of substrate using interposer channels |
| EP1874269A2 (en) * | 2005-04-19 | 2008-01-09 | Alza Corporation | Combination of tramadol and substances that comprise gabapentin |
| EP2019904A1 (en) * | 2006-05-17 | 2009-02-04 | Sandvik Intellectual Property AB | A rock-drilling tool, a drill rod and coupling sleeve |
| SA07280459B1 (ar) * | 2006-08-25 | 2011-07-20 | بيورديو فارما إل. بي. | أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني |
| WO2009012122A1 (en) * | 2007-07-13 | 2009-01-22 | Marvell World Trade Ltd. | Method for shallow trench isolation |
| AU2009223061B2 (en) * | 2008-03-11 | 2014-10-09 | Depomed Inc. | Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic |
| CN101933907A (zh) * | 2009-06-30 | 2011-01-05 | 北京天衡药物研究院 | 新型骨架缓释片及其制备方法 |
-
2012
- 2012-03-22 PT PT127174688T patent/PT2688556E/pt unknown
- 2012-03-22 HR HRP20150835TT patent/HRP20150835T1/hr unknown
- 2012-03-22 KR KR1020137027839A patent/KR101619579B1/ko active Active
- 2012-03-22 US US14/004,857 patent/US20140056979A1/en not_active Abandoned
- 2012-03-22 ME MEP-2015-116A patent/ME02189B/me unknown
- 2012-03-22 BR BR112013024585A patent/BR112013024585A8/pt not_active Application Discontinuation
- 2012-03-22 HU HUE12717468A patent/HUE026981T2/en unknown
- 2012-03-22 MX MX2013010987A patent/MX350875B/es active IP Right Grant
- 2012-03-22 DK DK12717468.8T patent/DK2688556T3/en active
- 2012-03-22 PH PH1/2013/501994A patent/PH12013501994A1/en unknown
- 2012-03-22 CA CA2831218A patent/CA2831218C/en active Active
- 2012-03-22 ES ES12717468.8T patent/ES2544735T3/es active Active
- 2012-03-22 PL PL12717468T patent/PL2688556T3/pl unknown
- 2012-03-22 CN CN201280020303.9A patent/CN103547259A/zh active Pending
- 2012-03-22 SI SI201230275T patent/SI2688556T1/sl unknown
- 2012-03-22 RS RS20150515A patent/RS54152B1/sr unknown
- 2012-03-22 EP EP20120717468 patent/EP2688556B1/en active Active
- 2012-03-22 WO PCT/IB2012/000595 patent/WO2012131463A2/en not_active Ceased
- 2012-03-22 AU AU2012235878A patent/AU2012235878B2/en active Active
- 2012-03-22 JP JP2014500486A patent/JP5964940B2/ja active Active
-
2013
- 2013-09-15 IL IL228441A patent/IL228441B/en active IP Right Grant
- 2013-10-22 ZA ZA2013/07862A patent/ZA201307862B/en unknown
-
2015
- 2015-08-03 CY CY20151100677T patent/CY1116579T1/el unknown
- 2015-09-09 SM SM201500209T patent/SMT201500209B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2013010987A (es) | 2014-10-13 |
| CY1116579T1 (el) | 2017-03-15 |
| PH12013501994A1 (en) | 2013-12-02 |
| KR20130135973A (ko) | 2013-12-11 |
| SI2688556T1 (sl) | 2015-09-30 |
| NZ616600A (en) | 2015-07-31 |
| US20140056979A1 (en) | 2014-02-27 |
| PL2688556T3 (pl) | 2015-10-30 |
| ME02189B (me) | 2016-02-20 |
| RS54152B1 (sr) | 2015-12-31 |
| BR112013024585A8 (pt) | 2018-01-09 |
| JP2014510094A (ja) | 2014-04-24 |
| ES2544735T3 (es) | 2015-09-03 |
| CA2831218C (en) | 2017-01-17 |
| EP2688556B1 (en) | 2015-05-06 |
| HUE026981T2 (en) | 2016-08-29 |
| IL228441A0 (en) | 2013-12-31 |
| CN103547259A (zh) | 2014-01-29 |
| AU2012235878B2 (en) | 2015-10-15 |
| ZA201307862B (en) | 2014-06-25 |
| WO2012131463A3 (en) | 2012-11-29 |
| EP2688556A2 (en) | 2014-01-29 |
| DK2688556T3 (en) | 2015-08-03 |
| JP5964940B2 (ja) | 2016-08-03 |
| SMT201500209B (it) | 2015-10-30 |
| HRP20150835T1 (hr) | 2015-09-11 |
| IL228441B (en) | 2019-05-30 |
| AU2012235878A1 (en) | 2013-05-02 |
| WO2012131463A2 (en) | 2012-10-04 |
| CA2831218A1 (en) | 2012-10-04 |
| KR101619579B1 (ko) | 2016-05-10 |
| PT2688556E (pt) | 2015-09-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12013501994A1 (en) | Controlled release pharmaceutical dosage forms | |
| MX2013008737A (es) | Formas de dosificacion oral para tasocitinib que comprende liberacion modificada. | |
| PH12014502462A1 (en) | Complement pathway modulators and uses thereof | |
| WO2012174158A3 (en) | Administration of benzodiazepine | |
| WO2014002051A3 (en) | Complement pathway modulators and uses thereof | |
| PH12016500072B1 (en) | Piperidinyl-indole derivatives complement factor b inhibitors and uses thereof | |
| WO2014002058A3 (en) | Complement pathway modulators and uses thereof | |
| WO2014009833A3 (en) | Complement pathway modulators and uses thereof | |
| CL2013002504A1 (es) | Preparacion farmaceutica solida recubierta que comprende a lo menos un ingrediente activo y porque el recubrimiento tiene un espesor de 0,1 a 100nm, de preferencia de 0,3 a 50 nm y mas preferentemente de 0,5 a 35 nm; y su metodo de preparacion | |
| JO2858B1 (en) | Pharmaceutical dosage images | |
| MY163083A (en) | Solid forms of a pharmaceutically active substance | |
| PH12013501842A1 (en) | Pharmaceutical compositions comprising metformin and a dpp-4 inhibitor or a sglt-2 inhibitor | |
| MX359288B (es) | Forma iv del clorhidrato de ivabradina. | |
| EP3513789A3 (en) | Prophylactic and therapeutic agents for fgfr3 diseases | |
| MY176793A (en) | Pharmaceutical tablet comprising acetylsalicylic acid and clopidogrel | |
| IN2014MN02236A (enExample) | ||
| PH12013502325A1 (en) | Drug delivery system | |
| EA201400737A1 (ru) | Система доставки на основе множества пеллет с немедленным высвобождением активного вещества | |
| PH12015500653A1 (en) | Combination drug comprising gemigliptin and metformin, and method for the preparation thereof | |
| MX360235B (es) | Composicion para evitar o tratar osteoporosis y metodo de manufactura para el mismo. | |
| MX2016006738A (es) | Procedimiento para producir material particulado inorganico. | |
| MX372834B (es) | PREPARACION FARMACEUTICA COMBINADA QUE COMPRENDE EL BLOQUEANTE DEL RECEPTOR DE LA ANGIOTENSINA II Y EL INHIBIDOR DE LA HMG-CoA REDUCTASA. | |
| GEP201706614B (en) | Compounds, pharmaceutical compositions and a method for the prophylaxis and treatment of the adhesion process | |
| JO3641B1 (ar) | تركيبة مضادات الفيروسات القهقرية | |
| MX365021B (es) | Composicion para tratar o prevenir enfermedades ocasionadas por permeabilidad vascular, que contiene como ingrediente activo imatinib o una sal farmaceuticamente aceptable del mismo. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |